These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12636887)

  • 1. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
    Miller KD
    Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
    [No Abstract]   [Full Text] [Related]  

  • 2. [Paclitaxel].
    Hino M; Kudo S
    Nihon Rinsho; 2002 May; 60 Suppl 5():343-8. PubMed ID: 12101685
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of metastatic colorectal cancer with monoclonal antibody to vascular endothelial growth factor: does the metastatic site make the difference?
    Graziano F; Cascinu S
    J Clin Oncol; 2003 Sep; 21(18):3542-3; author reply 3543. PubMed ID: 12972535
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab, bleeding, thrombosis, and warfarin.
    Kilickap S; Abali H; Celik I
    J Clin Oncol; 2003 Sep; 21(18):3542; author reply 3543. PubMed ID: 12972536
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
    Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future trends in anticancer chemotherapy].
    Kudoh S; Yamauchi S
    Nihon Rinsho; 2002 May; 60 Suppl 5():726-32. PubMed ID: 12101772
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
    Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
    Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
    [No Abstract]   [Full Text] [Related]  

  • 11. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Strategy of therapy for lung cancer].
    Kishi Y; Saijo N
    Nihon Rinsho; 2002 May; 60 Suppl 5():305-8. PubMed ID: 12101678
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of bevacizumab-based therapy in the management of breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2008 Oct; 8(5):402-10. PubMed ID: 18952553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 16. Genentech's anticancer Mab expected by November.
    Robertson D
    Nat Biotechnol; 1998 Jul; 16(7):615. PubMed ID: 9661186
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
    Yang JC; Haworth L; Sherry RM; Hwu P; Schwartzentruber DJ; Topalian SL; Steinberg SM; Chen HX; Rosenberg SA
    N Engl J Med; 2003 Jul; 349(5):427-34. PubMed ID: 12890841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
    Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
    Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.